Moderna, Inc. — Director's Dealing 2023

Mar 2, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2023-02-28

Reporting Person: Mock James M (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-28	Stock Option (Right to Buy)	$138.81	A	20040	Acquired	2033-02-28	Common Stock (20040)	Direct
2023-02-28	Restricted Stock Units	$0	A	5260	Acquired		Common Stock (5260)	Direct

Footnotes

F1: 25% of this option will vest and become exercisable on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F2: 25% of the shares subject to this restricted stock unit award will vest on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.